Those patients with PMS2 gene amplification have significantly shorter survival compared to non-CNAmp patients in each cancer type (GBM, HR = 1.53, 95% CI 1.22 to 1.92, P = 1.98×10-4; LGG, HR = 2.32, 95% CI 1.69 to 3.19, P = 2.33×10-7; HNSC, HR = 1.58, 95% CI 1.24 to 2.02, P = 2.22×10-4; OV, HR = 1.42, 95% CI 1.12 to 1.79, P = 3.48×10-3) (Figure 3B). Here, PMS2 is linked to cancer.